Cytokinetics Financial Statements From 2010 to 2022

CYTK -  USA Stock  

USD 39.76  0.97  2.50%

Cytokinetics financial statements provide useful quarterly and yearly information to potential Cytokinetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytokinetics financial statements helps investors assess Cytokinetics' valuation, profitability, and current liquidity needs.
There are currently ninety-eight fundamental signals for Cytokinetics that can be evaluated and compared over time across rivals. Please compare all of Cytokinetics prevailing fundamentals against the fundamentals between 2010 and 2022 to make sure the company is sustainable this year.
Cytokinetics Invested Capital Average is increasing as compared to previous years. The last year's value of Invested Capital Average was reported at 814.76 Million. The current Market Capitalization is estimated to increase to about 4.1 B, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (201.8 M).
  
Refresh
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics main balance sheet or income statement drivers, such as Gross Profit of 59.3 M, Interest Expense of 17.7 M or Operating Expenses of 277 M, as well as many exotic indicators such as Interest Coverage of 7.48, Long Term Debt to Equity of 1.16 or PPandE Turnover of 7.99. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules. It can also supplement various Cytokinetics Technical models. Continue to the analysis of Cytokinetics Correlation against competitors.

Cytokinetics Revenues

59.29 Million

Share

Cytokinetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets907.7 M841.3 M289.5 M
Increasing
Slightly volatile
Cash and Equivalents91.2 M112.7 M55.1 M
Increasing
Slightly volatile
Investments551.4 M511 M185.7 M
Increasing
Slightly volatile
Investments Current387.3 M359 M153.2 M
Increasing
Slightly volatile
Investments Non Current164.1 M152.1 M36.4 M
Increasing
Slightly volatile
Deferred Revenue107.9 M100 M48.9 M
Increasing
Slightly volatile
Property Plant and Equipment Net158 M146.4 M27.2 M
Increasing
Slightly volatile
Trade and Non Trade Receivables55.9 M51.8 M12.9 M
Increasing
Slightly volatile
Trade and Non Trade Payables22.8 M21.1 M6.5 M
Increasing
Slightly volatile
Total Liabilities644.6 M597.5 M195.6 M
Increasing
Slightly volatile
Shareholders Equity263.1 M243.9 M93.9 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(891.9 K)(869 K)17.2 K
Decreasing
Stable
Current Assets578 M535.7 M228 M
Increasing
Slightly volatile
Assets Non Current329.8 M305.6 M61.4 M
Increasing
Slightly volatile
Current Liabilities77.5 M71.9 M30.2 M
Increasing
Slightly volatile
Liabilities Non Current567.1 M525.6 M165.3 M
Increasing
Slightly volatile
Total Debt291.2 M269.9 M76.9 M
Increasing
Slightly volatile
Debt Current16 M14.9 M4.3 M
Increasing
Slightly volatile
Debt Non Current275.2 M255.1 M75.8 M
Increasing
Slightly volatile
Shareholders Equity USD263.1 M243.9 M93.9 M
Increasing
Slightly volatile
Cash and Equivalents USD91.2 M112.7 M55.1 M
Increasing
Slightly volatile
Total Debt USD291.2 M269.9 M76.9 M
Increasing
Slightly volatile
Accounts Payable7.8 M7.2 M4.3 M
Increasing
Slightly volatile
Receivables3.5 MM2.2 M
Increasing
Slightly volatile

Cytokinetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues59.3 M70.4 M37.3 M
Increasing
Slightly volatile
Selling General and Administrative Expense104.4 M96.8 M37 M
Increasing
Slightly volatile
Research and Development Expense172.6 M159.9 M77.3 M
Increasing
Slightly volatile
Operating Expenses277 M256.7 M114.5 M
Increasing
Slightly volatile
Interest Expense17.7 M16.4 M5.1 M
Increasing
Slightly volatile
Consolidated Income(221 M)(215.3 M)(86.5 M)
Decreasing
Slightly volatile
Net Income(221 M)(215.3 M)(86.5 M)
Decreasing
Slightly volatile
Preferred Dividends Income Statement Impact1.5 M1.2 M1.5 M
Decreasing
Slightly volatile
Net Income Common Stock(221 M)(215.3 M)(87.1 M)
Decreasing
Slightly volatile
Weighted Average Shares65.4 M76.9 M42.4 M
Increasing
Slightly volatile
Weighted Average Shares Diluted65.6 M76.9 M42.7 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(204.1 M)(198.9 M)(81.5 M)
Decreasing
Slightly volatile
Revenues USD59.3 M70.4 M37.3 M
Increasing
Slightly volatile
Net Income Common Stock USD(221 M)(215.3 M)(87.1 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(204.1 M)(198.9 M)(81.5 M)
Decreasing
Slightly volatile
Gross Profit59.3 M70.4 M37.3 M
Increasing
Slightly volatile
Operating Income(191.2 M)(186.3 M)(75.1 M)
Decreasing
Slightly volatile

Cytokinetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals(101.5 M)(98.9 M)(40.9 M)
Decreasing
Slightly volatile
Net Cash Flow from Financing345.2 M320 M115.7 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 151.6 M140.5 M47.2 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares345.2 M320 M93.2 M
Increasing
Slightly volatile
Net Cash Flow from Investing(151.7 M)(147.8 M)(50.1 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations(146.3 M)(142.5 M)(54.5 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents32 M29.7 M9.9 M
Increasing
Stable
Share Based Compensation29 M26.8 M10.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.9 M2.3 M1.2 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(3.02)(2.8)(2.1193)
Increasing
Stable
Earnings per Diluted Share(3.02)(2.8)(2.1209)
Increasing
Stable
Earnings per Basic Share USD(3.02)(2.8)(2.1193)
Increasing
Stable
Return on Average Equity(1.53)(1.492)0.174
Increasing
Very volatile
Return on Average Assets(0.33)(0.306)(0.408)
Increasing
Slightly volatile
Return on Invested Capital(0.27)(0.244)(0.574)
Increasing
Slightly volatile
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Profit Margin(3.3)(3.057)(4.5796)
Increasing
Slightly volatile
EBITDA Margin(3.01)(2.791)(4.2685)
Increasing
Slightly volatile
Return on Sales(3.05)(2.824)(4.3541)
Increasing
Slightly volatile
Asset Turnover0.150.10.2126
Decreasing
Very volatile
Enterprise Value over EBITDA(20.81)(20.273)(6.2165)
Decreasing
Slightly volatile
Enterprise Value over EBIT(20.53)(20.0)(6.0405)
Decreasing
Slightly volatile
Price to Earnings Ratio(16.71)(16.279)(5.0218)
Decreasing
Stable
Sales per Share0.990.9160.8482
Increasing
Stable
Price to Sales Ratio53.6949.7620.409
Increasing
Slightly volatile
Price to Book Value16.9115.6782.1269
Increasing
Very volatile
Debt to Equity Ratio2.642.45(0.5476)
Decreasing
Very volatile
Current Ratio8.567.4548.2962
Increasing
Very volatile
Free Cash Flow per Share(2.68)(2.489)(1.6207)
Increasing
Stable
Book Value per Share2.593.1722.3669
Decreasing
Slightly volatile
Tangible Assets Book Value per Share8.7510.9425.3908
Increasing
Slightly volatile
Total Assets Per Share5.466.774.7462
Increasing
Slightly volatile
Cash Flow Per Share0.120.11(1.1056)
Increasing
Slightly volatile
Return on Investment(63.45)(58.81)(59.4571)
Decreasing
Stable
Operating Margin17.0615.81(1.4553)
Increasing
Slightly volatile
Receivables Turnover15.9713.3619.9544
Decreasing
Slightly volatile
PPandE Turnover7.995.6111.5576
Decreasing
Very volatile
Cash and Equivalents Turnover0.730.840.7069
Increasing
Stable
Accounts Payable Turnover7.076.189.2157
Increasing
Very volatile
Accrued Expenses Turnover2.873.192.954
Increasing
Stable
Interest Coverage7.487.538.2329
Decreasing
Slightly volatile
Long Term Debt to Equity1.161.080.6016
Increasing
Slightly volatile
Quick Ratio14.5813.518.8325
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets96.395.4482.0802
Increasing
Stable
Revenue to Assets0.130.09410.1863
Decreasing
Very volatile

Cytokinetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(221 M)(215.3 M)(86.5 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(201.8 M)(196.6 M)(80.2 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(201.8 M)(196.6 M)(80.2 M)
Decreasing
Slightly volatile
Market Capitalization4.1 B3.8 B957.5 M
Increasing
Slightly volatile
Enterprise Value4.3 BB965.7 M
Increasing
Slightly volatile
Invested Capital999.9 M926.7 M275.4 M
Increasing
Slightly volatile
Average Equity116.7 M144.3 M72.9 M
Increasing
Stable
Average Assets758 M702.6 M249.4 M
Increasing
Slightly volatile
Invested Capital Average879.1 M814.8 M237.8 M
Increasing
Slightly volatile
Tangible Asset Value907.7 M841.3 M289.5 M
Increasing
Slightly volatile
Free Cash Flow(196.4 M)(191.4 M)(63.9 M)
Decreasing
Slightly volatile
Working Capital500.4 M463.8 M197.8 M
Increasing
Slightly volatile
Revenue Per Employee257.8 K272.3 K270.8 K
Increasing
Stable
Net Income Per Employee(856 K)(793.4 K)(563.2 K)
Decreasing
Slightly volatile

Cytokinetics Fundamental Market Drivers

Short Percent Of Float12.26%
Forward Price Earnings-12.26
Shares Short Prior Month9.19M
Average Daily Volume Last 10 Day1M
Average Daily Volume In Three Month917.42k
Date Short Interest15th of December 2021
Fifty Day Average37.93
Two Hundred Day Average36.24

Cytokinetics Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Cytokinetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytokinetics income statement, its balance sheet, and the statement of cash flows. Cytokinetics investors use historical funamental indicators, such as Cytokinetics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytokinetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytokinetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue100 M107.9 M
Revenues70.4 M59.3 M
Revenue to Assets 0.09  0.13 
Revenue Per Employee272.3 K257.8 K
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 184 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Cytokinetics Implied Volatility

    
  77.61  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Current Sentiment - CYTK

Cytokinetics Investor Sentiment

Most of Macroaxis users are currently bullish on Cytokinetics. What is your opinion about investing in Cytokinetics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Cytokinetics Correlation against competitors. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.